Abstract:Macroautophagy/autophagy is an evolutionarily conserved pathway responsible for clearing cytosolic aggregated proteins, damaged organelles or invading microorganisms. Dysfunctional autophagy leads to pathological accumulation of the cargo, which has been linked to a range of human diseases, including neurodegenerative diseases, infectious and autoimmune diseases and various forms of cancer. Cumulative work in animal models, application of genetic tools and pharmacologically active compounds, has suggested the potential therapeutic value of autophagy modulation in disease, as diverse as Huntington, Salmonella infection, or pancreatic cancer. Autophagy activation versus inhibition strategies are being explored, while the role of autophagy in pathophysiology is being studied in parallel. However, the progress of preclinical and clinical development of autophagy modulators has been greatly hampered by the paucity of selective pharmacological agents and biomarkers to dissect their precise impact on various forms of autophagy and cellular responses. Here, we summarize established and new strategies in autophagy-related drug discovery and indicate a path toward establishing a more efficient discovery of autophagy-selective pharmacological agents. With this knowledge at hand, modern concepts for therapeutic exploitation of autophagy might become more plausible.Abbreviations: ALS: amyotrophic lateral sclerosis; AMPK: AMP-activated protein kinase; ATG: autophagy-related gene; AUTAC: autophagy-targeting chimera; CNS: central nervous system; CQ: chloroquine; GABARAP: gamma-aminobutyric acid type A receptor-associated protein; HCQ: hydroxychloroquine; LYTAC: lysosome targeting chimera; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MTOR: mechanistic target of rapamycin kinase; NDD: neurodegenerative disease; PDAC: pancreatic ductal adenocarcinoma; PE: phosphatidylethanolamine; PIK3C3/VPS34: phosphatidylinositol 3-kinase catalytic subunit type 3; PtdIns3K: class III phosphatidylinositol 3-kinase; PtdIns3P: phosphatidylinositol 3-phosphate; PROTAC: proteolysis-targeting chimera; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; SQSTM1/p62: sequestosome 1; ULK1: unc-51 like autophagy activating kinase 1.

Molecular Modulators and Receptors of Selective Autophagy: Disease Implication and Identification Strategies

Targeting selective autophagy and beyond: From underlying mechanisms to potential therapies

Selective autophagy in cancer: mechanisms, therapeutic implications, and future perspectives

Targeting autophagy in disease: established and new strategies

Autophagy Regulators As Potential Cancer Therapeutic Agents: A Review

Selective autophagy of intracellular organelles: Recent research advances

Targeting autophagy drug discovery: Targets, indications and development trends

Targeting autophagy with small-molecule activators for potential therapeutic purposes

Targeting selective autophagy in CNS disorders by small-molecule compounds

Identification and Functional Studies of New Autoph-agy Protein Machinary

Autophagy Intertwines with Different Diseases—Recent Strategies for Therapeutic Approaches

Epigenetic and post-translational modifications in autophagy: biological functions and therapeutic targets

Drug discovery by targeting the protein‒protein interactions involved in autophagy

The mechanisms and roles of selective autophagy in mammals

Mechanistic Insights into Selective Autophagy Subtypes in Alzheimer’s Disease

Small molecule regulators of autophagy identified by an image-based high-throughput screen.

Selective autophagy as a therapeutic target for neurological diseases

The Regulation of the Autophagic Network and Its Implications for Human Disease

Small‐Molecule Regulators of Autophagy and Their Potential Therapeutic Applications

Targeting Autophagy to Overcome Human Diseases

High Throughput Screening for Drug Discovery of Autophagy Modulators